BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, July 12, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

March 20, 2019

View Archived Issues

Optiscan secures $20M series E to support continuous ICU bedside blood monitoring

Laboratory work for intensive care unit (ICU) patients can be laborious, time-consuming and repetitive for providers, as well as painful, draining and tedious for patients who are already among the sickest in the hospital. Hayward, Calif.-based startup Optiscan Biomedical Corp. aims to enable continuous, blood-based patient monitoring in the ICU that alerts care providers when vital measures stray out of range. Patients who remain in-range on these indicators have been shown to have fewer complications, shorter hospital stays and reduced costs. Read More

Canadian researchers unveil low-cost optical laser probe to aid in diagnosis of skin cancer

Read More

Affluent Medical presents positive endovascular prosthesis study results

Read More

Appointments and advancements

Read More

Regulatory front

Read More

Financings

Read More

Product briefs

Read More

Other news to note

Read More

BioWorld MedTech's Oncology Extra

Read More

Study suggests that all with secondary regurgitation benefit from Mitraclip

NEW ORLEANS – The question of when a study is a failure is at times entirely in the eyes of the beholder. However, a study unveiled in the Crescent City suggests that echocardiography cannot distinguish which patients will benefit most from the Mitraclip device for secondary mitral valve regurgitation. At the same time, a secondary study that looked at quality-of-life issues provided a supportive context for the device vs. medical management – an increasingly important consideration as physicians, regulators and device makers move deeper into this era of personalized medicine. Read More

Oncimmune scoops up Protagen, gains platform for identifying autoantibodies

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 10, 2026.
  • 3D rendering of an antibody drug conjugate

    ‘Target-high but uptake-defective’ state identified in ADC resistance

    BioWorld
    Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
  • Wainua autoinjector

    Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

    BioWorld
    News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
  • Art concept for medical research

    FENS 2026: Shedding light on the sheddome

    BioWorld
    At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
  • Silhouette with keyhole

    FENS 2026: Next-gen biologics take on brain disease

    BioWorld
    Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing